Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.
1 report, 0 independent
Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.Also in this story
- Bruker and Humana are facing soft demand from academic institutions and a slowdown in the biopharma market.
- Richard Tobin cited positive margin mix from growth platforms for BioPharma.
- Penumbra is facing growth impacts due to uncertainties regarding FDA review timelines and revenue decline in China.
- Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.
The entities involved
-
Padraig McDonnell
Irish business executive; CEO-elect of Agilent Technologies
Nothing else this week.
-
Patrick Donnelly
researcher ORCID ID = 0000-0002-9910-0794
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet